Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes

被引:17
|
作者
Johnston, S. [1 ]
Janning, S. W. [2 ]
Haas, G. P. [3 ]
Wilson, K. L. [1 ]
Smith, D. M. [1 ]
Reckard, G. [3 ]
Quan, S-P [3 ]
Bukofzer, S. [3 ]
机构
[1] Thomson Reuters, Washington, DC USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
[3] Astellas Pharma Global Dev, Deerfield, IL USA
关键词
EXTENDED-RELEASE; RISK-FACTORS; PREVALENCE; INCONTINENCE; THERAPY; TERMINOLOGY; SYMPTOMS; IMPACT; WOMEN; RATES;
D O I
10.1111/j.1742-1241.2012.03009.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: This retrospective administrative claims-based study evaluated comparative persistence and adherence to overactive bladder (OAB) medications in US patients with and without diabetes. Methods: Patients = 18 years who initiated OAB medications between 1 January 2005 and 30 June 2008 were analysed from the Truven Health MarketScan (R) Commercial and Medicare Supplemental databases. A 12-month baseline period prior to OAB medication initiation was used to classify patients into diabetes and non-diabetes cohorts, and measure demographic and clinical characteristics. Patients in each cohort were directly matched 1 : 1 based on index year, age, gender and geographic region. Multiple logistic regression was used to compare cohorts on outcomes of = 80% adherence to OAB medications and refilling a second OAB medication prescription. Coxs proportional hazards model compared time to non-persistence with OAB medications between both cohorts. Results: In total, 36,560 patients were included in each cohort. Compared with the non-diabetes cohort, the diabetes cohort had 21.5% higher odds of = 80% adherence to OAB medications, 16.6% higher odds of filling a second OAB medication prescription and 10.3% lower hazard of non-persistence with OAB medications during a 12-month evaluation period. Conclusions: Patients with diabetes were more persistent and adherent to OAB medications and had higher odds of filling a second medication prescription than patients without diabetes. Further research is needed to identify factors responsible for these findings.
引用
收藏
页码:1042 / 1051
页数:10
相关论文
共 50 条
  • [31] DO PATIENTS DISCONTINUE OVERACTIVE BLADDER MEDICATIONS AFTER SACRAL NEUROMODULATION?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen
    Lee, Una
    Lucioni, Alvaro
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S569 - S569
  • [32] Efficacy of solifenacin with or without tamsulosin in patients with overactive bladder
    范治璐
    China Medical Abstracts(Surgery), 2011, 20 (04) : 244 - 244
  • [33] Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
    Yeowell, Gillian
    Smith, Philip
    Nazir, Jameel
    Hakimi, Zalmai
    Siddiqui, Emad
    Fatoye, Francis
    BMJ OPEN, 2018, 8 (11):
  • [34] Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
    Chapple, Christopher R.
    Nazir, Jameel
    Hakimi, Zalmai
    Bowditch, Sally
    Fatoye, Francis
    Guelfucci, Florent
    Khemiri, Amine
    Siddiqui, Emad
    Wagg, Adrian
    EUROPEAN UROLOGY, 2017, 72 (03) : 389 - 399
  • [35] Adherence to antimuscarinics in children with overactive bladder
    Fortin, Alexandra
    Morin, Valerie
    Ramsay, Sophie
    Gervais, Pascale
    Bolduc, Stephane
    PAEDIATRICS & CHILD HEALTH, 2017, 22 (05) : 255 - 258
  • [36] MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT DIABETES MELLITUS
    Zhu, B.
    Zhao, Z.
    Bayt, T.
    Bae, J. P.
    McCollam, P. L.
    Anderson, J.
    LeNarz, L.
    VALUE IN HEALTH, 2009, 12 (07) : A343 - A343
  • [37] A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
    Jameel Nazir
    Zalmai Hakimi
    Florent Guelfucci
    Amine Khemiri
    Francis Fatoye
    Ana María Mora Blázquez
    Marta Hernández González
    BMC Urology, 18
  • [38] A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
    Nazir, Jameel
    Hakimi, Zalmai
    Guelfucci, Florent
    Khemiri, Amine
    Fatoye, Francis
    Blazquez, Ana Maria Mora
    Gonzalez, Marta Hernandez
    BMC UROLOGY, 2018, 18
  • [39] Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder
    Illiano, Ester
    Agro, Enrico Finazzi
    Natale, Franca
    Balsamo, Raffaele
    Costantini, Elisabetta
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (06) : 1035 - 1042
  • [40] Assessing the Impact of Overactive Bladder Medications on Cognition
    Maldonado, Darlene Vargas
    Schulte, Phillip J.
    Latuche, Laureano Rangel
    Vassilaki, Maria
    Petersen, Ronald C.
    Occhino, John A.
    Linder, Brian J.
    UROGYNECOLOGY, 2025, 31 (01): : 10 - 17